Last reviewed · How we verify

Continuous rocuronium infusion

University Hospital, Antwerp · Phase 3 active Small molecule

Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate, causing muscle paralysis.

Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate, causing muscle paralysis. Used for Neuromuscular blockade during general anesthesia for surgical procedures, Neuromuscular blockade in mechanically ventilated intensive care unit patients.

At a glance

Generic nameContinuous rocuronium infusion
SponsorUniversity Hospital, Antwerp
Drug classNon-depolarizing neuromuscular blocking agent
TargetNicotinic acetylcholine receptor (motor endplate)
ModalitySmall molecule
Therapeutic areaAnesthesia / Critical Care
PhasePhase 3

Mechanism of action

Rocuronium binds reversibly to nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and triggering muscle contraction. Continuous infusion maintains sustained neuromuscular blockade during prolonged surgical procedures or in mechanically ventilated intensive care patients. The drug is metabolized hepatically and renally, with effects reversible by sugammadex (a selective relaxant binding agent) or spontaneous recovery over time.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: